-
Stapokibart Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Stapokibart Injection (trade name: 康悦达) of Chengdu Kangnuoxing Biopharma, Inc. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis in adults who are inadequately controlled by topical medications or for whom topical medications are not indicated.
-
Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug, Sulbactam Sodium for Injection/Durlobactam Sodium for Injection (co-packaged) (trade name: 鼎优乐/XACDURO) of Entasis Therapeutics, Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Ivonescimab Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the Ivonescimab Injection (trade name: 依达方) of Akeso Inc. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Rilertinib Mesylate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Rilertinib Mesylate Tablets (trade name: 圣瑞沙) of Nanjing Sanhome Pharmaceutical Limited Company is approved for marketing by China NMPA.
-
Envonalkib Citrate Capsules Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Envonalkib Citrate Capsules (trade name: 安洛晴) of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA.
-
Insulin icodec Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the insulin icodec injection (trade name: 诺和期/Awiqli) of Novo Nordisk A/S is approved for marketing by China NMPA.
